UNC Lineberger Comprehensive Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, UNC Lineberger Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count).

366 total trials 79 currently recruiting 209 completed early-phase tilt top decile by trial count

UNC Lineberger Comprehensive Cancer Center: 366 sponsored US clinical trials, 79 recruiting.

UNC Lineberger Comprehensive Cancer Center sponsors 366 registered US clinical trials on ClinicalTrials.gov, 79 of them currently recruiting, and 209 completed. 2 of these trials are in Phase 3-4 (later-stage) and 157 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 29 trials.

Top-decile sponsor footprint

UNC Lineberger Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 52/100

209 of 246 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

366 total, page 8 of 8

TERMINATED Phase 2

Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00280748

COMPLETED Phase 1

Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

NCT00266097

COMPLETED Phase 2

Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

NCT00280735

COMPLETED Phase 1

Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women

NCT00099008

TERMINATED Phase 2

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer

NCT00088985

COMPLETED

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00280761

COMPLETED Phase 2

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

NCT00280787

COMPLETED Phase 1

Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer

NCT00280176

TERMINATED Phase 2

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

NCT00073970

COMPLETED NA

Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer

NCT00182728

COMPLETED Phase 2

Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery

NCT00233974

COMPLETED Phase 1

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

NCT00237627

COMPLETED Phase 1

Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

NCT00006108

COMPLETED Phase 2

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

NCT00006110

COMPLETED Phase 2

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

NCT00003392

COMPLETED Phase 1

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus

NCT00002984

← Previous Page 8 of 8

Phase Distribution

PhaseTrial count
Phase 1 71
Phase 2 86
Phase 3 1
Phase 4 1

What is open in the UNC Lineberger Comprehensive Cancer Center pipeline

79 recruiting of 366 indexed (22% open); 209 completed (57%).

Phase mix: 2 late (III/IV) vs 157 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (29 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

UNC Lineberger Comprehensive Cancer Center: open-pipeline peers nationwide

Peers matched on 366 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 0%5%10%15%20%25% Total trials Recruiting share UNC Lineberger Comprehensive Cancer CenterRoswell Park Cancer InstituteUniversity of California, IrvineNew York State Psychiatric InstituteNorthwell HealthWomen and Infants Hospital of Rhode IslandMerck Sharp & DohmeHenry M. Jackson Foundation for the Advancement of Military MedicineAbbVie
UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 366 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

What to do with this UNC Lineberger Comprehensive Cancer Center page

366 registered trials is a research-attention snapshot, not an endorsement of UNC Lineberger Comprehensive Cancer Center or any single study.

  • 79 of UNC Lineberger Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition UNC Lineberger Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. UNC Lineberger Comprehensive Cancer Center pipeline card: 366 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.